15 Cancer Drugs Are in Short Supply, FDA reports: The Kiplinger Letter
The U.S. is working to address cancer drug shortages caused by manufacturing and supply chain woes.
To help you understand what the U.S. is doing to address problems and challenges in the healthcare sector, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
Uncle Sam has made some progress in reducing cancer drug shortages by working with manufacturers to restart U.S. production facilities that were previously shut down, as well as securing vital overseas supplies.
One drug, cisplatin, often used to treat ovarian, bladder and testicular cancer has already returned to near 100% pre-shortage levels of supply. However, The U.S. still has an overall shortage of 15 cancer drugs, per the Food and Drug Administration (FDA), because of manufacturing and supply chain problems.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In 2022, manufacturing site closures reduced the U.S. supply of cisplatin, (used to treat bladder cancer, testicular cancer, or ovarian cancer), carboplatin (used for ovarian cancer) and methotrexate (used for leukemia, breast and lung cancer, and more) by nearly half, leading to treatment delays for cancer patients.
One survey by the National Comprehensive Cancer Network in June found that 70% of its members were experiencing a cisplatin shortage, while virtually all their members found carboplatin difficult to come by. Around 20% of cancer patients rely on platinum-based chemotherapy drugs, such as cisplatin and carboplatin, for treatment, according to federal health statistics.
Several U.S. manufacturers have exited this market in recent years, increasing American reliance on foreign imports from China and India, in particular. It remains unclear how Uncle Sam will address this long-term problem, which may ultimately require using government demand to bolster manufacturing.
One bill now under consideration by Congress, the Drug Shortage Prevention Act, would require manufacturers to report anticipated shortages ahead of time.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
- Costs of 34 Medicare Drugs To Be Capped Until December
- Select Health Aims to Offer Lower Drug Prices Via New Partnership
- How to Save on Prescription Medication
-
4% and Chill? Find Out If This Distribution Rule Fits Your RetirementTake this simple quiz to discover whether the 4% Rule will work for you in retirement.
-
Oregon Tax Kicker in 2026: What's Your Refund?State Tax The Oregon kicker for 2025 state income taxes is coming. Here's how to calculate your credit and the eligibility rules.
-
Will IRS Budget Cuts Disrupt Tax Season? What You Need to KnowTaxes The 2026 tax season could be an unprecedented one for the IRS. Here’s how you can be proactive to keep up with the status of your return.
-
Trump Reshapes Foreign PolicyThe Kiplinger Letter The President starts the new year by putting allies and adversaries on notice.
-
Congress Set for Busy WinterThe Kiplinger Letter The Letter editors review the bills Congress will decide on this year. The government funding bill is paramount, but other issues vie for lawmakers’ attention.
-
The Kiplinger Letter's 10 Forecasts for 2026The Kiplinger Letter Here are some of the biggest events and trends in economics, politics and tech that will shape the new year.
-
Special Report: The Future of American PoliticsThe Kiplinger Letter The Political Trends and Challenges that Will Define the Next Decade
-
What to Expect from the Global Economy in 2026The Kiplinger Letter Economic growth across the globe will be highly uneven, with some major economies accelerating while others hit the brakes.
-
Shoppers Hit the Brakes on EV Purchases After Tax Credits ExpireThe Letter Electric cars are here to stay, but they'll have to compete harder to get shoppers interested without the federal tax credit.
-
The Economy on a Knife's EdgeThe Letter GDP is growing, but employers have all but stopped hiring as they watch how the trade war plays out.
-
Banks Are Sounding the Alarm About StablecoinsThe Kiplinger Letter The banking industry says stablecoins could have a negative impact on lending.
